20 July 2022

The European Cancer Patient Coalition is pleased to announce the appointment of the Scientific Committee, for the mandate June 2022 - May 2025, whose members are:

Kathi Apostolidis – Chair of the Scientific Committee of the European Cancer Patient Coalition;

Prof. Mark Lawler - Associate Pro-Vice-Chancellor and Professor of Digital Health-Faculty of Medicine, Health and Life Sciences - Chair in Translational Cancer Genomics - Patrick G Johnston Centre for Cancer Research - Queen's University Belfast;

Prof. Francoise Meunier – Vice President of the FEAM - Federation of the European Academies of Medicine

- Fellow and Member of the Science Policy Committee of EACS-European Academy of Cancer Science;

Ass. Prof. Nicola Normanno - President, International Quality Network for Pathology (IQN Path) and President, Italian Cancer Society (SIC);

Prof. Ulrik Ringborg - Director - Cancer Center Karolinska - Karolinska University Hospital Solna;

Dr. Kostas Stamatopoulos - Hematologist – Director INAB/CERTH Institute of Applied Biosciences-Greece - Coordinator of the National Network of Precision Oncology (2018-2022) - Visiting Professor-Karolinska Institute;

Kathi Apostolidis, ECPC Past President, will chair the newly appointed Scientific Committee. Kathi Apostolidis has long experience in the ECPC Board, as she was ECPC’s elected President in June 2019 and has served many years. Kathi is a breast cancer survivor and an expert cancer patient advocate, graduate of the Philosophy and Law Schools of the University of Athens. On the national level, she is a co-founder and President of the Hellenic Cancer Federation – ELLOK, the Greek national cancer patients umbrella organization.

ECPC relies on its’ Scientific Committee, an expert consultative body to the Board, to support the development and implementation of the scientific activities of the association in cancer policy and research, and to provide guidance to the Board of Directors on key scientific topics relevant to the work of the association.

Since ECPC was established in 2003, its key areas of activity are cancer policy and research, as well as capacity building so that our members can successfully advocate for cancer policy and research in their countries. As per ECPC Statute, we expect the new Scientific Committee to play a significant role in providing guidance and foresight to the Board of Directors.